A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US

PharmacoEconomics

Volumn 15, Issue SUPPL. 1, 1999, Pages 23-37

  Lacey, L ^a   Mauskopf, J ^b   Lindrooth, R ^c   Pham, S ^d   Saag, M ^e   Sawyer, W ^f  

^a GLAXOSMITHKLINE   (United Kingdom)

^b RTI INTERNATIONAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOVIRIDE; PLACEBO; PROTEINASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LAMIVUDINE; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; UNITED STATES; ZIDOVUDINE;

EID: 0032928989     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915001-00003     Document Type: Article

References (26)

1. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. Pharmacoeconomics 1996; 10 (2): 109-13
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997 Oct; 11 (12): F101-F105
3. Paul S, Ziecheck W, Gilbert HM, et al. Impact of HAART on rates and types of hospitalizations at a New York city hospital [abstract 205]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, IL, 1998: 117
4. McInick D, Greiner D, Little P, et al. Impact of aggressive management of HIV infection on clinical outcome and cost of care within a health maintenance organization [abstract 201]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, IL, 1998: 116
5. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR Trial. Lancet 1997; 349: 1413-21
6. Lacey L, Hill A, Mauskopf JA. The incidence of opportunistic infections and hospitalisations in HIV patients treated with lamivudine/zidovudine. Presented at the 3rd International Conference of Drug Therapy in HIV Infection; 1996 Nov 3-7; Birmingham, UK, 1996, AIDS 1996; 10 Suppl. 2: S28
7. Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 1998; 13 (3): 277-88
8. Schulman KA, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114: 798-802
9. Moore RD, Hidalgo J, Bareta JC, et al. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1994; 7: 349-54
10. Simpson K, Hatziandreu EJ, Andersson F, et al. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300μI in 5 European countries. Pharmacoeconomics 1994; 6 (6): 553-62
11. Mauskopf JA, Lacey LA, Kempel A, et al. The cost-effectiveness of treatment with lamivudine and zidovudine compared to zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care 1998; 4 (7): 1004
12. Chancellor JV, Hill AM, Sabin CA, et al. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997; 12 (1); 54-66
13. Johannesson M, Weinstein M. On the decision rules of cost effectiveness analysis. J Health Econ 1993; 12; 459-67
14. Physician's Desk Reference. 51st ed. Montvale, NJ: Medical Economics, 1997
15. St Anthony's complete resource-based relative value scale (RBRVS). Reston, VA: St Anthony Publishing, Inc., 1997
16. Childress KJ, Saag M, Clougherty C, et al. Annual cost estimation and resource utilization for treating opportunistic illnesses associated with AIDS [abstract N-23]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1997 Sep 28-Oct 1; Toronto, Canada, 1997: 386
17. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection ami expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17): 1-19
18. Bureau of Labor Statistics 1998. http://www.bls.gov/top20.html
19. Polsky D, Glick HA, Wilke R, et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243-52
20. Anis AH, Hogg RS, Wang X, et al. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Pharmacoeconomics 1998; 13 (6): 697-705
21. Lacey L, Gill MJ. Lamivudine reduces healthcare resource use when added to zidovudine containing regimens in patients with HIV infection. Pharmacoeconomics 1999; 15 Suppl. 1: 13-22
22. Gallagher D, Helliger JA, Master RJ. The CMA experience: applying combination antiretroviral therapy in a US inner city, advanced AIDS population. Will viral rebound translate to increased costs? [abstract no. 32405] Presented at the 12th World AIDS Conference; 1998 Jun 29-Jul 3; Geneva, Switzerland
23. Gable CB, Tierce JC, Simison D, et al. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retroviral 1996; 12: 413-20
24. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retroviral 1997; 14: 223-31
25. Carpenter CCJ, Fisch MA, Hammer SL, et al. Antiviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS society - USA Panel. JAMA 1998; 280: 78-86
26. Adams Jr HP, Woolson RF, Clarke WR, et al. Design of the trial of Org 10172 in acute stroke treatment (TOAST). Control Clin Trials 1997; 18 (4): 358-77